-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $10

Benzinga·04/10/2026 13:27:52
Listen to the news
Guggenheim analyst Michael Schmidt maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy and raises the price target from $6 to $10.